Diversa plans to use its DirectEvolution technology, which generates randomized protein variants, to help engineer monoclonal antibodies. Medarex will bring its experience developing human monoclonal antibodies and its "extensive collaborative network" to the deal, Diversa president and CEO Jay Short said in a statement.